Annette von Delft
M.D, Ph.D.
Head of Anti-Infectives, Centre for Medicines Discovery
Annette von Delft works on the discovery and development of novel small molecule inhibitors against viruses, bacteria and fungi. Her work covers projects from early target validation, target enablement, molecule discovery and preclinical development.
Annette's current focus is the preclinical development of a novel antivirals for pandemic preparedness, targeting coronaviruses, flaviviruses and enteroviruses, as part of the global consortia COVID Moonshot and ASAP (https://asapdiscovery.org/ ). On these projects, she works in close collaboration with Drugs for Neglected Disease initiative (DNDi).
Annette joined the BRC team in 2018 as a translational scientist with a focus on inflammation and immunity, and has initiated a range of early target validation projects in immunology, infectious disease and neuroscience.
Annette trained as a medical doctor at University of Leipzig (Germany) and received her D.Phil in Clinical Medicine at the University of Oxford in 2010, working on HCV T cell immunology and vaccine development under the supervision of Prof Eleanor Barnes. She then completed her medical foundation programme at Oxford University Hospitals.
Recent publications
-
Open science discovery of potent noncovalent SARS-CoV-2 main protease inhibitors.
Journal article
Boby ML. et al, (2023), Science, 382
-
Accelerating antiviral drug discovery: lessons from COVID-19.
Journal article
von Delft A. et al, (2023), Nat Rev Drug Discov
-
Turning high-throughput structural biology into predictive inhibitor design.
Journal article
Saar KL. et al, (2023), Proc Natl Acad Sci U S A, 120
-
Incoming HIV virion-derived Gag Spacer Peptide 2 (p1) is a target of effective CD8+ T cell antiviral responses.
Journal article
Yang H. et al, (2021), Cell Rep, 35
-
Open Science Discovery of Potent Non-Covalent SARS-CoV-2 Main Protease Inhibitors
Journal article
Boby ML. et al, (2020)